Rob Berman, M.D, is a board member and advisor to multiple biotechnology companies that are focused on developing drugs for central nervous system disorders.  His research career started in academia at Yale, where he studied the mechanism of action of antidepressants and novel treatments for psychiatric disorders including exploiting the value of already-approved agents such as ketamine (Berman et al, 2000) and pindolol.  For over 20 years he has worked within the industry, first at Pfizer and then Bristol-Myers Squibb in clinical development roles, including leading the program for aripiprazole in depression, for which he developed novel clinical trial design that achieved three out of three highly statistically significant trials).  In 2013, he co-founded Biohaven Pharmaceuticals (NYSE:BHVN) and was Chief Medical Officer until 2019.   He completed his undergraduate degree at Yale University in Molecular Biophysics and Biochemistry and medical degree from the Mt Sinai School of Medicine in 1990.  He is currently an Adjunct Professor of Psychiatry at the Yale University School of Medicine and has over 70 peer-reviewed publications.